Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
1 Ergebnisse für "eduardo" unter Somagenetix
Browse by Communities & Collections - Zurich Open Repository and Archive
... conversation on bio art with Eduardo Kac. Journal of Latin American Cultural Studies, 26(2):279-297. De ... Oliveira, Eduardo Jorge (2017). “Vender alguma coisa, dar certo na vida”: A passagem do poema ao objeto na ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
1 Ergebnisse für "eduardo" unter University of Zurich
Browse by Communities & Collections - Zurich Open Repository and Archive
... , Adriana (2020). Barcelona/New York: Linkgua. de Oliveira, Eduardo Jorge ; Sterzi, Eduardo ; Stigger ... , Verônica (2020). Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo Sterzi e Verônica ...
NovaGo Therapeutics AG
http://www.novagotherapeutics.com
8952 Schlieren, Wagistrasse 27
NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in the treatment of cerebral stroke and spinal cord injury. NovaGo is developing human antibody therapeutics against Nogo-A. Nogo-A is the most potent inhibitor of nerve fiber regeneration. Anti-NogoA treatment promotes recovery of function in several animal models of stroke. Novago Therapeutics' anti-NogoA treatment represents a novel, regenerative approach for stroke. Recovery of function in stroke and other neurological disorders will be a clinical breakthrough and have a major economic impact on health care.
NovaGo Therapeutics AG
Wagistrasse 27
8952 Schlieren